Amyloid beta amyloidosis in Alzheimer's disease

D. L. Price, S. S. Sisodia, S. E. Gandy

Research output: Contribution to journalReview article

Abstract

The presence of amyloid deposits in the parenchyma of the amygdala, hippocampus, and neocortex Is a major histopathological hallmark of Alzheimer's disease. The principal component of amyloid is amyloid beta, a 39-43 amino acid peptide comprised of a portion of the transmembrane domain and the extracellular domain of the amyloid precursor proteins. Amyloid precursor proteins occur as several amyloid beta-containing isoforms of 695, 751, and 770 amino acids. In cultured cells, amyloid precursor proteins mature through the constitutive secretory pathway, and some cell-surface-bound amyloid precursor proteins are cleaved by an enzyme, designated as alpha-secretase, within the amyloid beta domain, an event that precludes amyloid beta amyloidogenesis. Two additional pathways of amyloid precursor protein processing include an endosomal/lysosomal pathway that generates a complex set of amyloid precursor protein-related membrane-bound fragments, some of which contain the entire amyloid beta sequence; and, by mechanisms not fully understood, secretion of amyloid beta 1-40 into the conditioned medium in vitro and its presence in cerebrospinal fluid in vivo. The intracellular sites of enzymes responsible for proteolytic cleavage at the amino- and carboxyl-termini of amyloid beta, termed gamma- and beta-secretase, respectively, have not been identified. Molecular genetic investigations have identified a variety of mutations in the amyloid precursor protein gene that segregate with early-onset familial Alzheimer's disease and with hereditary cerebral hemorrhage with amyloid, Dutch type. Several of these mutations appear to influence amyloid precursor protein processing and result in the production of higher levels or longer amyloid beta-related peptides that are inherently more fibrillogenic. Although a variety of lines of evidence implicate amyloid precursor protein and amyloid beta in Alzheimer's disease, the mechanism(s) by which amyloid beta influences the biology and vulnerability of neural cells is not fully clear. Amyloid beta toxicity is being explored in vitro and in vivo. Finally, recent progress has been made in the generation of transgenic mice expressing amyloid precursor protein or amyloid beta that recapitulate a subset of the pathology observed in Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)268-274
Number of pages7
JournalCurrent opinion in neurology
Volume8
Issue number4
DOIs
StatePublished - Jan 1 1995

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Amyloid beta amyloidosis in Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this